Since anti-IL-23 is currently FDA approved for the treatment of other pro-inflammatory diseases, we believe our studies will open avenues for the development of promising strategies against the development and treatment of NAFLD. The gene discussed is IL37; the disease is metabolic dysfunction-associated steatotic liver disease.